Skip to content

GENETIC DETERMINANTS OF MONOAMINE METABOLITE LEVELS IN HUMAN CEREBROSPINAL FLUID

GENETIC DETERMINANTS OF MONOAMINE METABOLITE LEVELS IN HUMAN CEREBROSPINAL FLUID - GDMA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38098
Enrollment
1000
Registered
2008-07-22
Start date
2008-08-21
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depression

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Military personnel and civilians referred for surgical procedures under spinal anesthesia whose four grandparents were born in The Netherlands will be included.

Exclusion criteria

Exclusion criteria: Exclusion criteria are: age 58 years old and the use of benzodiazepines shortly before entering the operating theatre.

Design outcomes

Primary

MeasureTime frame
Levels of HVA, 5-HIAA and MHPG in CSF will be tested for association with a set of single nucleotide polymorphisms (SNPs). The DNA region of interest is the chromosome region that is homologous to the region that was recently found to be linked with MAM levels in vervet monkeys. Once identified, the effect of associated polymorphisms on RNA expression of monoamine genes will be investigated. MAM levels and associated genotypes will be related to specific behavioral traits, as assessed through validated questionnaires.

Secondary

MeasureTime frame
As a secondary parameter, we will measure CSF amino acid concentrations and correlate these quantitatively to candidate genotypes and behavioral traits as assessed with the abovementioned questionnaires.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)